Best daily deals

Links on Android Authority may earn us a commission. Learn more.

Galaxy Nexus injunction obtained by Apple in the U.S.

June 30, 2012

A few days ago U.S. District Judge Lucy Koh, presiding over an Apple vs Samsung case in California, awarded Apple a pre-trial injunction against Galaxy Tab 10.1 sales in the country. Apple then posted a $2.6 million bond – that’s supposed to protect the company in case the decision gets overturned in an appeal and cover for potential damages incurred by Samsung due to lack of sales of the banned product – and the injunction became effective.

In case that wasn’t enough bad news for the Android device maker, the same Judge awarded Apple another injunction against a different Samsung product yesterday. This time we’re talking about the Galaxy Nexus, a device that’s available from Verizon and Sprint in the region, that has also received a pre-trial sales ban. Koh said:

Apple has made a clear showing that, in the absence of a preliminary injunction, it is likely to lose substantial market share in the smartphone market and to lose substantial downstream sales of future smartphone purchases and tag-along products.

In order for the injunction to become effective, Apple will have to post another bond in the amount of $95 million.

However, hope is not lost for Samsung, as Judge Koh scheduled tow more hearings, on Sunday and Monday, in which she will decide whether to put the injunctions – Galaxy Tab 10.1 and Galaxy Nexus, respectively – on hold pending appeal.

Samsung had little to say about this unsatisfactory ruling but the company will surely appeal Friday’s decision:

We will take all available measures, including legal action, to ensure the Galaxy Nexus remains available to consumers

This is just the last predicament in a complex and tedious legal battle between the two giants, currently the main players in the mobile business when it comes to handset and tablet sales and profits. The two companies are suing and countersuing each other in 10 countries across four continents, in over 30 patent-based trials.